InvestSMART

LTR Pharma Ltd (ASX:LTP)

ALERT: Price-sensitive ASX Announcement for LTP
Current share price for LTP : $0.505 0.035 (7.45%)+
Announcement
Release
11 Aug 2026 8:32AM
Price at Release
$0.470
Full Release
download
Summary
LTR Pharma Ltd announced positive results from a real-world study involving 147 men using SPONTAN®, a rapid-onset intranasal vardenafil spray for erectile dysfunction. The study, conducted in Australia, reported a 93% response rate among men seeking greater convenience and spontaneity. This includes a 64% improvement in erectile hardness and penetration among post-prostatectomy patients, a group that often finds traditional oral therapies ineffective. The findings suggest that SPONTAN could be a viable alternative for men inadequately served by oral PDE5 inhibitors like Viagra. These results are significant as LTR Pharma aims to expand its commercial reach in the U.S. with SPONTAN and ROXUS®, supported by upcoming partnerships and regulatory filings.
Key Points
  • 93% response rate among men seeking convenience with SPONTAN
  • 64% of post-prostatectomy patients reported improvements
  • SPONTAN seen as alternative to oral PDE5 inhibitors
  • Focus on U.S. market expansion via FDA 505(b)(2) pathway
  • SPONTAN available in Australia under special access schemes
  • Study highlights unmet needs in prostate cancer-related ED treatment
  • LTR Pharma's commercial strategy includes partnerships in the U.S.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.